Detalhe da pesquisa
1.
Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.
Am J Prev Cardiol
; 11: 100372, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36039183